In accordance with Article 152 of Regulation (EU) 2019/6, all marketing authorisations for veterinary medicinal products (VMPs) granted under Directive 2001/82/EC, as amended, must be updated to align their product information with QRD template version 9.These updates must be completed at the latest by 29 January 2027, after which all products…

Precautionary batch recall, as there may be glass splinters in the bottles

Recall due to possible contamination with glass splinters

Recall due to reduced release of active pharmaceutical ingredient

Many of the offered "peptides" are classified as medicinal products without marketing authorisation by the Austrian Federal Office for Safety in Health Care (BASG) depending on their composition, concentration, effects and scientific data.

The BASG warns against illegal medicinal products (illegal medicinal product by presentation) marketed under the misleading name "GLP-1" because of their claims.

The Federal Office for Safety in Health Care (BASG) warns of a counterfeit medical device that could be mistaken for the legitimate product "Juvéderm Ultra 4" from the manufacturer "Allergan Aesthetics, an AbbVie company".

The Federal Office for Safety in Health Care (BASG) warns against the use of rapid tests for the detection of sexually transmitted diseases (STDs) that were distributed via the website „thuistest.shop“ and “stdheimtest.de“. Based on the information available to the BASG, the legal compliance of the affected products cannot be sufficiently…

The Federal Office for Safety in Health Care (BASG) warns lay users against the use of rapid tests for the detection of sexually transmitted diseases (STDs) that were distributed via the website „thuistest.shop“ and “stdheimtest.de“. In contrast to the website’s operator claim, all listed products are not intended for self-testing by lay users, but…

Recall due to deviations from quality standards at the production site